Table 2.
Effect on nonvertebral/hip fracture rates (from randomized controlled trials)
| Nonvertebral | Hip | |||
|---|---|---|---|---|
| Osteoporosis (without prevalent vertebral fractures) | Established osteoporosis (with prevalent vertebral fractures) | Osteoporosis (without prevalent vertebral fractures) | Established osteoporosis (with prevalent vertebral fractures) | |
| Raloxifene | NA | ● | NA | NA |
| Alendronate | ■ | ■ | NA | ■ |
| Risedronate | NA | ■ | NA | ■ |
| Ibandronate | NA | ● | NA | NA |
| Zoledronate | ■ | NA | ■ | NA |
| Teriparatide | NA | ■ | NA | NA |
| Strontium Ranelate | ● | ■ | ● | ▲ |
| Denosumab | ■ | NA | ■ | NA |
NA no evidence available
■ Denotes a preplanned analysis in the entire study population
▲ Denotes a preplanned analysis on a subset of the study population
● Denotes a post hoc analysis